274 related articles for article (PubMed ID: 33160934)
1. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
6. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Zhang YC; Wang JN; Ma SY; Cai J; Su N; Huang HQ; Li ZM; Xia ZJ; Huang H; Liu PP; Xia Y; Cai QQ
Br J Haematol; 2022 Jan; 196(1):127-135. PubMed ID: 34618912
[TBL] [Abstract][Full Text] [Related]
7. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Choi Y; Diefenbach CS
Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
[TBL] [Abstract][Full Text] [Related]
9. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C; Allen P; Herrera AF
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
[TBL] [Abstract][Full Text] [Related]
10. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
11. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM
Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
14. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
16. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of pembrolizumab for classical Hodgkin lymphoma.
Manji F; Laister RC; Kuruvilla J
Expert Rev Hematol; 2022 Apr; 15(4):285-293. PubMed ID: 35389317
[TBL] [Abstract][Full Text] [Related]
18. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
[TBL] [Abstract][Full Text] [Related]
20. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
